Stephen Doberstein Net Worth

The estimated Net Worth of Stephen K Doberstein is at least $1.26 Million dollars as of 3 June 2021. Stephen Doberstein owns over 3,333 units of Dicerna Pharmaceuticals Inc stock worth over $127,387 and over the last 15 years he sold DRNA stock worth over $1,133,363. In addition, he makes $0 as Independent Director at Dicerna Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Stephen Doberstein DRNA stock SEC Form 4 insiders trading

Stephen has made over 22 trades of the Dicerna Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 3,333 units of DRNA stock worth $127,387 on 3 June 2021.

The largest trade he's ever made was exercising 396,323 units of Dicerna Pharmaceuticals Inc stock on 6 November 2017 worth over $3,776,958. On average, Stephen trades about 19,242 units every 50 days since 2010. As of 3 June 2021 he still owns at least 3,333 units of Dicerna Pharmaceuticals Inc stock.

You can see the complete history of Stephen Doberstein stock trades at the bottom of the page.

Stephen Doberstein biography

Dr. Stephen K. Doberstein Ph.D. serves as Independent Director of the Company. Dr. Doberstein served as the Senior Vice President, Research and Chief Scientific Officer of Nektar Therapeutics, Inc. (“Nektar Therapeutics”), a publicly-traded biotechnology company, from January 2010 to November 2017, and as Senior Vice President of R&D and Chief Research and Development Officer from November 2017 to October 2019. Dr. Doberstein has been serving as Chief Scientific Fellow and a lead scientific advisor to Nektar Therapeutics since October 2019. From October 2008 through December 2009, Dr. Doberstein served as Vice President of Research at XOMA (US) LLC (NASDAQ: XOMA), a publicly-traded company. From July 2004 until October 2008, he served as Vice President of Research at Five Prime Therapeutics, Inc., a clinical-stage biotechnology company. From September 2001 until July 2004, Dr. Doberstein was Vice President of Research at Xencor, Inc., a clinical-stage biotechnology company. From 1997 to 2001, he held various pharmaceutical research positions at Exelixis, Inc. (“Exelixis”). Prior to working at Exelixis, Dr. Doberstein was a Howard Hughes Doctoral Fellow and a Muscular Dystrophy Association Fellow and Senior Postdoctoral Fellow. Dr. Doberstein received his Ph.D. in Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine and received a B.S. in Chemical Engineering from the University of Delaware. The Nominating and Corporate Governance Committee believes that Dr. Doberstein’s scientific and business expertise, including his diversified background as an executive officer and researcher at biopharmaceutical companies, provide him with the qualifications and skills to serve as a member of our Board of Directors.

How old is Stephen Doberstein?

Stephen Doberstein is 61, he's been the Independent Director of Dicerna Pharmaceuticals Inc since 2020. There are 3 older and 10 younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.

What's Stephen Doberstein's mailing address?

Stephen's mailing address filed with the SEC is C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.

Insiders trading at Dicerna Pharmaceuticals Inc

Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo, and Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.

What does Dicerna Pharmaceuticals Inc do?

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.

Complete history of Stephen Doberstein stock trades at Dicerna Pharmaceuticals Inc and Nektar Therapeutics

Dicerna Pharmaceuticals Inc executives and stock owners

Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Douglas Fambrough,
  President, Chief Executive Officer, Director
• Robert Ciappenelli,
  Chief Commercial Officer
• Bob Brown,
  Executive Vice President, Research and Development, Chief Scientific Officer
• James Weissman,
  Chief Operating Officer, Executive Vice President
• J. Kevin Buchi,
  Independent Chairman of the Board
• Marc Kozin,
  Independent Director
• Anna Protopapas,
  Independent Director
• Adam Koppel,
  Independent Director
• Stephen Hoffman,
  Independent Director
• Martin Freed,
  Independent Director
• Cynthia Smith,
  Independent Director
• Patrick Gray,
  Independent Director
• Ling Zeng,
  Chief Legal Officer and Secretary
• Shreeram Aradhye,
  Executive Vice President, Chief Medical Officer
• Douglas Pagan,
  Chief Financial Officer
• Stephen Doberstein,
  Independent Director
• Capital Management, Llc Kol...,
  
• Partners Viii, L.P.Blair Ja...,
  
• Theodore Ashburn,
  See Remarks
• John B Green,
  Chief Financial Officer
• David Madden,
  Director
• Pankaj Bhargava,
  Chief Medical Officer
• Viii Associates, L.P.Blair ...,
  
• Bruce Peacock,
  Director
• Ralf Rosskamp,
  Chief Medical Officer
• Brian K Halak,
  Director
• Regina M. Paglia,
  Chief Human Resources Officer
• Capital Life Sciences Inves...,
  
• Capital Management, Llcra C...,
  
• Peter Kolchinsky,
  Director
• Bart W Wise,
  SVP, Legal Affairs
• Dennis Langer,
  Director
• James C Blair,
  10% owner
• Venture Partners V Lp Skyli...,
  
• James E Dentzer,
  Chief Financial Officer
• James E Deerfield Mgmt L.P....,
  
• James E Deerfield Mgmt L.P....,
  
• Vincent J Miles,
  Director
• Capital Management Llcbrook...,
  
• Kathleen K Schoemaker,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Nicole Vitullo,
  10% owner
• Brian H Dovey,
  10% owner
• Jesse I Treu,
  10% owner
• Viii Associates, L.P. Dp,
  10% owner
• Partners Viii, L.P. Domain,
  10% owner